Cargando…

Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers

PURPOSE: The Pituitary Society established the concept and mostly qualitative parameters for defining uniform criteria for Pituitary Tumor Centers of Excellence (PTCOEs) based on expert consensus. Aim of the study was to validate those previously proposed criteria through collection and evaluation o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giustina, A., Uygur, M. M., Frara, S., Barkan, A., Biermasz, N. R., Chanson, P., Freda, P., Gadelha, M., Kaiser, U. B., Lamberts, S., Laws, E., Nachtigall, L. B., Popovic, V., Reincke, M., Strasburger, C., van der Lely, A. J., Wass, J. A. H., Melmed, S., Casanueva, F. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539196/ https://www.ncbi.nlm.nih.gov/pubmed/37640885 http://dx.doi.org/10.1007/s11102-023-01345-0

Ejemplares similares

Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement
por: Casanueva, Felipe F., et al.
Publicado: (2017)

A consensus on the diagnosis and treatment of acromegaly complications
por: Melmed, S., et al.
Publicado: (2012)

Pituitary tumor centers of excellence for Cushing’s disease
por: Couselo, Marcos, et al.
Publicado: (2022)

A Consensus Statement on acromegaly therapeutic outcomes
por: Melmed, Shlomo, et al.
Publicado: (2018)

A Pituitary Society update to acromegaly management guidelines
por: Fleseriu, Maria, et al.
Publicado: (2020)

PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial
por: Elenkova, Atanaska, et al.
Publicado: (2022)

LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly
por: Samson, Susan, et al.
Publicado: (2022)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study
por: Giustina, Andrea, et al.
Publicado: (2019)

Low vitamin D levels predict outcomes of COVID-19 in patients with both severe and non-severe disease at hospitalization
por: di Filippo, Luigi, et al.
Publicado: (2023)

Center of Biomedical Research Excellence in Cardiovascular Health
por: Wenner, Megan M., et al.
Publicado: (2017)

One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2021)

Durable biochemical response and safety with oral octreotide capsules in acromegaly
por: Samson, Susan L, et al.
Publicado: (2022)

OR23-07 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

MON-LB55 Biochemical Control of Most Patients Reverting to Injectable Long-Acting Somatostatin Receptor Ligands Is Achieved After One Dose: Results From the Phase 3, Randomized, Double Blind, Placebo-Controlled Optimal Study
por: Fleseriu, Maria, et al.
Publicado: (2020)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
por: Samson, Susan L, et al.
Publicado: (2020)

Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?
por: Ho, Ken, et al.
Publicado: (2021)

MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study
por: Samson, Susan Leanne, et al.
Publicado: (2020)

SAGIT(®): clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study
por: Giustina, Andrea, et al.
Publicado: (2015)

Rare Cardiovascular Disease Care: Centers of Excellence or Excellence of Centers?
por: Fine, Nowell M., et al.
Publicado: (2023)

Clinical Biology of the Pituitary Adenoma
por: Melmed, Shlomo, et al.
Publicado: (2022)

The NETting of pituitary adenoma: a gland illusion
por: Ho, Ken K. Y., et al.
Publicado: (2022)

MON-314 Analysis of Adverse Events in Adult Patients with Acromegaly Receiving Oral Octreotide Capsules: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Labadzhyan, Artak, et al.
Publicado: (2020)

MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

The emerging osteo-metabolic phenotype of COVID-19: clinical and pathophysiological aspects
por: di Filippo, Luigi, et al.
Publicado: (2021)

Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
por: Labadzhyan, Artak, et al.
Publicado: (2021)

Correction to: Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
por: Labadzhyan, Artak, et al.
Publicado: (2021)

Hypocalcemia in COVID-19: Prevalence, clinical significance and therapeutic implications
por: di Filippo, Luigi, et al.
Publicado: (2021)

The osteo-metabolic phenotype of COVID-19: an update
por: di Filippo, Luigi, et al.
Publicado: (2022)

Metastatic 4S neuroblastoma with excellent outcome in Saudi cancer center
por: AlZhrani, Waheed A., et al.
Publicado: (2021)

Centers for Oceans and Human Health: contributions to an emerging discipline
por: Laws, Edward A, et al.
Publicado: (2008)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

Diabetes Center of Excellence Hypoglycemia Emergency Preparedness Project
por: Cobb, Ellen C., et al.
Publicado: (2018)

Building project management centers of excellence
por: Bolles, Dennis
Publicado: (2002)

International Centers of Excellence for Malaria Research
por: Rao, Malla R.
Publicado: (2015)

OR32-6 Pre-Surgical GH Levels Predict the Risk of Morphometric Vertebral Fracture, Which Is an Early and Frequent Event in the Natural History of Acromegaly
por: Frara, Stefano, et al.
Publicado: (2019)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

Mapping of the current transition of care practice for patients with pituitary disease at Endo-ERN reference centers
por: Shishkov, Savi R, et al.
Publicado: (2022)

Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly
por: Freda, Pamela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bot9f60jvc3j3d19krsc0ssh4q